NCT04509102 (Stimulant-rTMS) is a EARLY_PHASE1 clinical trial of Adderall-XR in Major Depressive Disorder, sponsored by University of California, Los Angeles.

Who is sponsoring NCT04509102?

NCT04509102 is sponsored by University of California, Los Angeles.

What drugs are being tested in NCT04509102?

Interventions in NCT04509102: Adderall-XR, Placebo.

What condition does NCT04509102 study?

NCT04509102 studies Major Depressive Disorder.

Is NCT04509102 still recruiting?

NCT04509102 is currently enrolling by invitation. Last updated 3 February 2026.

Last reviewed 2026-02-03 · How we verify

NCT04509102: Stimulant-rTMS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder

ENROLLING BY INVITATION EARLY_PHASE1 Last updated 3 February 2026

What this trial tests

EARLY_PHASE1 trial testing Adderall-XR in Major Depressive Disorder in 30 participants. Enrolling by invitation.

Timeline

27 September 2021

Primary endpoint
1 December 2027

1 December 2027

Quick facts

Lead sponsor	University of California, Los Angeles
Phase	EARLY_PHASE1
Status	ENROLLING BY INVITATION
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	30
Start date	27 September 2021
Primary completion	1 December 2027
Estimated completion	1 December 2027
Sites	1 location across United States

Drugs / interventions tested

Adderall-XR
Placebo

Conditions studied

Major Depressive Disorder — all drugs for Major Depressive Disorder →

Sponsor

University of California, Los Angeles

Who can join

Adults 18 to 65, any sex, with Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study analyzes the affects or Adderall extended-release (XR) in Subjects receiving brain stimulation therapy for the treatment of Major Depressive Disorder. Subjects will be assigned by chance to active or placebo group. Active group will be asked to take one 15 mg pill once daily of Adderall XR (amphetamine) and the Placebo group will be asked take an identical appearing tablet/capsule, one tablet by mouth daily. The placebo tablet has no active ingredients and has no affect on the body or mind. With the exception of the study drug, all other study activities between both groups will be identical. Subjects will use the assigned study drug two weeks before therapy and throughout the first 10 therapy treatments. A total of seven(7) visits will be required for screening, drug assignment, and completion of mood assessments. This study will enroll a total of 30 Subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Adderall-XR

Trials testing the same drug.

NCT05650775 — Biomarkers of ADHD Treatment Response · Phase 1 · completed

Other recruiting trials for Major Depressive Disorder

Currently open trials in the same condition.

NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting

Other University of California, Los Angeles trials

Trials by the same sponsor.

NCT04846517 — rTMS for Aneroxia Nervosa in Youth · NA · not yet recruiting
NCT06701760 — Sodium Lactate in Severe TBI · Phase 2 · not yet recruiting
NCT04996667 — Effect of iNO in Patients With Submassive and Massive PE · Phase 2 · withdrawn
NCT05067387 — Evaluation of Oral THC and CBD in Men and Women · Phase 1 · not yet recruiting
NCT07534696 — Evaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04509102 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Los Angeles
Last refreshed: 3 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04509102.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing